Anticancer Drugs Dasatinib Oncology Pharmacology Physiotherapy

Dasatinib (Mechanism of Action)

In this article, we will discuss Dasatinib (Mechanism of Action)

In this article, we will discuss Dasatinib (Mechanism of Action). So, let’s get started.

Dasatinib is a kinase inhibitor. The chemical name for dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide, monohydrate. The molecular formula is C22H26ClN7O2S • H20, which corresponds to a formula weight of 506.02 (monohydrate). The anhydrous free base has a molecular weight of 488.01.

Mechanism of Action

Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), C-KIT, EPHA2, and PDGFRB. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.

In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines
overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.